Symptoms of liver disease include fatigue, malaise, anorexia, nausea, jaundice, acholic stools, liver tenderness or hepatomegaly. 4.1 Therapeutic indications. Ivosidenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).Ketoconazole (Systemic): Nevirapine may decrease the serum concentration of Ketoconazole (Systemic). Seek immediate medical attention if you develop signs of muscle problems (such as wasting or decrease in muscle size, Rarely, lamivudine and zidovudine have caused severe (sometimes fatal) Lamivudine/zidovudine is not a cure for HIV infection. Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine. Treatment with lamivudine and zidovudine tablet should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity, which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations.Mycobacterium avium infection, cytomegalovirus, Pneumocystis jiroveciiwith zidovudine, a component of Lamivudine and Zidovudine Tablets, has been associated with loss of subcutaneous fat. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. When this combination is necessary, use immediate-release nevirapine (avoid extended-release nevirapine) at a dose of 200 mg twice daily with no lead-in (per adult/adolescent HIV guidelines). Discontinuation of Lamivudine and Zidovudine Tablets should be considered as medically appropriate. Available for Android and iOS devices. No vaginal tumors were found at the lowest dose.In rats, 2 late-appearing (after 20 months), non-metastasizing vaginal squamous cell carcinomas occurred in animals given the highest dose. DOXOrubicin (Conventional) may diminish the therapeutic effect of Zidovudine.DOXOrubicin (Liposomal): May enhance the adverse/toxic effect of Zidovudine. This has been observed with delavirdine. Women tend to be at higher risk for development of Lamivudine, Nevirapine, and Zidovudine Tablets-associated rash [ Inform patients that the important toxicities associated with zidovudine are neutropenia and/or anemia. <1%, postmarketing, and/or case reports: Autoimmune disease, Graves disease, Guillain-Barre syndrome, immune reconstitution syndrome, polymyositisSevere, life-threatening, and in some cases fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine, a component of lamivudine/nevirapine/zidovudine tablets. Safety was also assessed in trial BI 1100.882 (ACTG 180), an open-label trial of nevirapine (n=37) in which subjects were followed for a mean duration of 33.9 months (range: 6.8 months to 5.3 years, including long-term follow-up in 29 of these subjects in trial BI 1100.892). There were no differences in pregnancy-related adverse events between the treatment groups. The 14-day lead-in period with nevirapine daily dosing has been observed to decrease the incidence of rash and must be followed.Patients must be monitored intensively during the first 18 weeks of therapy with lamivudine/nevirapine/zidovudine tablets to detect potentially life-threatening hepatotoxicity or skin reactions. Lamivudine/Zidovudine tablets should not be used for children weighing less than 14 kg, since doses can not be appropriately adjusted for the weight of the child. Monitor patients for signs of lipoatrophy and consider switching to a non-zidovudine-containing regimen if lipoatrophy occurs.• Hepatic impairment: Use is not recommended in patients with hepatic impairment.• Pancreatitis: Use with caution in patients with a history of pancreatitis or at risk for developing pancreatitis. Some combinations may be specifically contraindicated.


We comply with the HONcode standard for trustworthy health information - Each film-coated tablet contains 100 mg of lamivudine. WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXOCITY, SKIN REACTIONS, HEMATOLOGIC TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY, EXACERBATIONS OF HEPATITIS BHEPATOTOXICITY: Severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine, a component of Lamivudine, Nevirapine, and Zidovudine Tablets. [see Boxed Warning, Warnings and Precautions (5.4)]. Each film-coated tablet contains the active ingredients 150 mg of lamivudine USP, 200 mg of nevirapine USP, and 300 mg of zidovudine USP and the inactive ingredients are colloidal silicon dioxide, hydroxy propyl methyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone k-25, and sodium starch glycolate. If overdose occurs, the patient should be monitored and standard supportive treatment applied as required.Lamivudine and Zidovudine Tablets, USP are combination tablets containing lamivudine and zidovudine. lamivudine, nevirapine, and zidovudine tablet, film coatedWe comply with the HONcode standard for trustworthy health information - Drug formulations: tablets by mouth Combivir: lamivudine 150 mg and zidovudine 300 mg (scored). The choice of new antiretroviral agents to be used in combination with nevirapine should take into consideration the potential for cross resistance. Instruct patients developing signs or symptoms of liver disease or severe skin reactions to discontinue Lamivudine, Nevirapine, and Zidovudine Tablets and seek medical attention immediately, including performance of laboratory monitoring. Monitor nevirapine response closely.Rifamycin Derivatives: May decrease the serum concentration of Zidovudine.Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. Lamivudine, Nevirapine, and Zidovudine Tablets should not be restarted following severe skin rash or hypersensitivity reaction. Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L per kg, suggesting that nevirapine is widely distributed in humans. After the initial 18week period, frequent clinical and laboratory monitoring should continue throughout lamivudine, zidovudine, and nevirapine tablets treatment [ Because Lamivudine, Nevirapine, and Zidovudine Tablets is a fixed-dose combination and cannot be adjusted, it is not recommended for:Liquid and solid oral formulations of the individual components of Lamivudine, Nevirapine, and Zidovudine Tablets are available for these populations.